Therapeutic stem cell composition and stimulant, facilitator, accelerator, and synergizer thereof, growth factor, anti-inflammatory composition and uses thereof

Abstract

The present invention relates to a non-invasive medical therapy and a composition for avoiding organ transplantation, or controlling biological rejection of transplanted organs, or treating organs under consideration for replacement by transplant, and otherwise treating aged, diseased and/or abnormal tissues and/or organs. More specifically, the non-invasive medical therapy involves administering to a patient an elemental nutritional feeding comprising a free amino acid profile simulating and/or replicating a targeted diseased or transplanted tissue and/or organ. The subject invention provides methods of inactivating reactive component epitopes of moieties pathogenic substances or producing immunogenic compositions containing pathogenic substances comprising contacting pathogenic substances, or compositions containing pathogenic substances, with super critical carbon dioxide or liquid nitrogen. Similar benefits are produced using high HLB surfactants also reducing carcinogenic factors. In various embodiments, the pathogenic reactive components, epitopes, moieties or substances are inactivated and processed into immunogenic compositions. The subject invention also provides oral mucosal delivery systems for the subject therapeutic compositions and/or medications, and/or vaccines that avert the need for parenteral administration in the medical and veterinary fields.

1 .- 33 . (canceled)  
     
     
         34 . A composition for treatment of damaged tissue comprising: 
 a. amino acids or salts thereof present at a molar ratio which is characteristic of sheep milk or goat milk;    b. at least one essential lipid;    c. at least one protective antioxidant lipid; and    d. at least one mucopolysaccharide.    
     
     
         35 . A composition comprising: 
 a. amino acids present at a molar ratio which is characteristic of sheep milk or goat milk; and    b. at least one essential lipid.    
     
     
         36 . The composition of  claim 35 , further comprising chondroitin sulfate and eicosapentanoic acid.  
     
     
         37 . A composition comprising: 
 a. amino acids present at a molar ratio which is characteristic of sheep milk or goat milk;    b. at least one lipid;    c. at least one mono- or di-saccharide sugar;    d. at least one vitamin;    e. at least one mineral; and    f. at least one antioxidant.    
     
     
         38 . The composition of  claim 34 , further comprising collagen.  
     
     
         39 . The composition of  claim 34 , wherein the at least one mucopolysaccharide is chondroitin sulfate.  
     
     
         40 . The composition of  claim 34 , wherein the at least one protective antioxidant lipid is eicosapentanoic acid.  
     
     
         41 . The composition of  claim 36 , further comprising collagen.  
     
     
         42 . The composition of  claim 35  wherein the essential lipid comprises a fatty acid.  
     
     
         43 . The composition of  claim 35  wherein the essential lipid comprises a phospholipid.  
     
     
         44 . A mucosal delivery system for delivering an antigen or drug to a patient or animal, the mucosal delivery system comprising:  
       a chylomicron vehicle having a diameter ranging from about 0.5 microns to about 1 micron, the chylomicron vehicle comprising: 
 a. liquid fat from an oil selected from the group consisting of palm kernel oil, coconut oil, corn oil and mixtures thereof; and  
 b. at least one surfactant selected from the group consisting of polyglycerol polyricinolate, phosphatidylcholine, glycerine and polysorbate 80.  
 
     
     
         45 . The mucosal delivery system according to  claim 44 , further comprising: 
 c. at least one flavoraid.    
     
     
         46 . The mucosal delivery system according to  claim 45 , wherein the flavoraid is selected from the group consisting of chocolate, white chocolate free of caffeine and theobromine.  
     
     
         47 . A method for reducing the allergenicity of allergens, the method comprising:  
       applying to an allergen source, a solution comprising: 
 a. polysorbate 80 at a concentration ranging from about 0.25% to about 2%;  
 b. an acceptable carrier at a concentration ranging from about 0.1% to about 50%; and  
 c. a non-toxic alcohol at a concentration ranging from about 0.1% to about 50%.  
 
     
     
         48 . The method according to  claim 47 , wherein the acceptable carrier is at a concentration ranging from about 0.1% to about 5%.  
     
     
         49 . The method according to  claim 47 , wherein the acceptable carrier is glycerine.  
     
     
         50 . The method according to  claim 47 , wherein the non-toxic alcohol is at a concentration ranging from about 0.1% to about 5%.  
     
     
         51 . The method according to  claim 47 , wherein the non-toxic alcohol is ethyl alcohol or isopropyl alcohol.  
     
     
         52 . The method according to  claim 47 , further comprising phosphatidylcholine at a concentration ranging from about 0.5% to about 1%; and sodium lauryl sulfate at a concentration ranging from about 0.5% to about 1%.  
     
     
         53 . The method according to  claim 47 , wherein the allergen source is selected from the group consisting of a poison ivy plant, lipophilic allergenic weed and animal dander.  
     
     
         54 . The method according to  claim 47 , wherein the reduction in allergenicity is measured using a Bradford assay or ELISA.  
     
     
         55 . The method according to  claim 54 , wherein there is a reduction in allergenicity of at least 45-fold as measured by the Bradford assay.  
     
     
         56 . The method according to  claim 54 , wherein there is a reduction in allergenicity of at least 5% as measured by ELISA.